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Background: The World Health Organization recommends malaria be diagnosed by standard microscopy or rapid
diagnostic test (RDT) before treatment. RDTs have been used with greater frequency in the absence of matching
blood slide confirmation in the majority of RDT reported cases in Mimika Regency, Papua Province, Indonesia. Given
the importance of RDT in current health system as point-of-care tool, careful validation of RDT product performance
for providing accurate malaria diagnosis is critical.
Methods: Plasmotec Malaria-3 (XW-P07) performance was evaluated by comparing it with paired blood film
microscopy and quantitative real-time PCR (qPCR). Consecutive whole blood samples were derived from one clinic
in Mimika as part of routine passive malaria case detection. RDT results were read by two trained technicians and
interpreted by consensus. Expert microscopic examination of blood slides was cross-checked by observer-blinded
second reader and a third examiner if discordant between examinations. qPCR was used as the ‘gold standard’,
followed by microscopy for the outcome/disease variable. Comparison analysis included sensitivity (Sn), specificity
(Sp), positive and negative predictive values (PPV & NPV), and other diagnostic screening performance measures for
detecting Plasmodium falciparum and Plasmodium vivax infections.
Results: Overall malaria positive samples from qPCR was 42.2% (175/415 samples); and from matching blood slides
40.5% (168/415) of which those infections with relatively low parasite densities ≤100/μl blood was 5.7% of P. falciparum
and 16.5% of P. vivax samples examined. Overall RDT performance when compared with microscopy for detecting
P. falciparum was Sn:92%, Sp:96.6%, PPV:88%, NPV:97.8%, Kappa:0.87; and for P. vivax Sn:72.9%, Sp:99.1%, PPV:95.4%,
NPV:93.4%, Kappa:0.79. Overall RDT performance when compared with qPCR for detecting P. falciparum was Sn:92%,
Sp:96.6%, PPV:88%, NPV:97.8%, Kappa:0.87; and for P. vivax Sn:66%, Sp:99.1%, PPV:95.4%, NPV:90.9%, Kappa:0.73.
Conclusions: Plasmotec Malaria-3 test showed good overall performance scores in precision for detecting P. falciparum,
but lower values regarding sensitivity and negative likelihood ratio for detecting P. vivax, a finding partly associated with
greater frequency of lower density P. vivax infections compared to P. falciparum in this study. In particular, the negative
likelihood ratio (>0.1) for P. vivax detection indicates RDT lacked sufficient discriminating exclusion power falling below
general acceptance criteria.
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Malaria remains a serious public health problem in
Indonesia. Approximately 45% of the populations across
the archipelago are at risk for malaria infection [1], with
417,819 confirmed malaria cases in 2012. However, the
national annual parasite incidence (API) i.e., the number
of people per 1,000 populations that experienced at least
one case of malaria in a 12-month period, had decreased
from 4.68‰ in 1990 to 1.69‰ in 2012. This is an en-
couraging development towards an overall national tar-
get API of below 1‰ by year 2030 [2].
While several areas have witnessed significant reduc-
tions in malaria prevalence, other regions (e.g., eastern
Indonesia) have remained problematic for performing ef-
fective control strategies because of remoteness, lack of
adequate resources and sufficient budgets to combat
both vectors and parasites. Papua and West Papua prov-
inces of Indonesia, located on the western half of the is-
land of New Guinea, have the highest malaria burdens
in the country, with recent province-wide APIs of 60.6‰
and 52.3‰, respectively [3]. All four species of Plasmo-
dium parasites are present in Papua, with Plasmodium
falciparum and Plasmodium vivax as the most common
infections, followed with far less frequency by Plasmo-
dium ovale and Plasmodium malariae. In high transmis-
sion areas, mixed species infections are not uncommon.
Mimika Regency, covering a vast area of the southern
part of Papua Province, had an API of 531.3‰ in 2012
with an overall P. falciparum/P. vivax case infection ra-
tio of 1.3:1 [4]. Other report had estimated the average
API closer to 876‰ in the immediate Timika area, the
capital of Mimika, and where the vast majority of the
population resides [5].
The World Health Organization (WHO) recommends
all clinically suspected malaria cases have parasitological
confirmed diagnosis, using either a malaria-specific rapid
diagnostic test (RDT) or direct visualization of parasites
using microscopy, before treatment [6]. For more than a
century, use of microscopy has been considered the ‘gold
standard’ for malaria diagnosis, species identification,
and to quantify parasitaemia [7]. Various public and pri-
vate health care facilities in the Timika area can perform
standard microscopic diagnosis of malaria, but this is
often compromised by the poor condition and mainten-
ance of the microscope and the irregular availability of a
trained laboratory technician. In many of the remote
villages in the Mimika Regency (particularly those with-
out electricity, skilled staff, or microscopist) and most
public-run clinics, only RDT is used for malaria diagno-
sis. INDEC Diagnostics (Jakarta, Indonesia) manufac-
tures a multi-panel malaria RDT Plasmotec Malaria-3
(hereafter referred to using the product catalog number
XW-P07) that meets ISO 13485:2003 standards [8]. In-
cluding the company’s internal assessment of the RDT,there is only one known published evaluation of this
product [9] that occurred in southern Sumatra; there-
fore, a performance evaluation of this RDT was deemed
prudent if this product was to be recommended for
wider use in the Mimika area. RDT quality (accuracy and
precision) is especially important given the infrequent use
or absence of routine microscopy or matching blood film
confirmation in the majority of instances in Papua.
Among other criteria, a useful and effective RDT must
have sufficiently high sensitivity to be able to accurately
identify as many ‘true’ malaria cases as possible, espe-
cially in areas where reliable microscopy is not available
or used infrequently. This is particularly important so
that infections can be effectively and specifically treated
based on parasite species. The screening sensitivity of an
RDT can be influenced by the epidemiological character-
istics and infection dynamics in the target population.
As parasite antigen concentrations in the blood and
parasitaemia levels can vary due to multiple host and
parasite factors, the performance level of an RDT can be
similarly affected depending on the malaria-endemic
population involved in the product assessment [10].
Establishing test performance accuracy for disease
screening should be considered before investing and
committing to a specific product. Although certain tests
may be relatively inexpensive and easy to use, they must
be valid and provide consistent reproducible results.
Test accuracy describes the diagnostic strength of the
association between the predictor variable (RDT result)
and outcome variable (disease) as measured against a
‘gold standard’ test. The most common and useful com-
plementary measures for evaluating a test are sensitivity
(the proportion of true diseased persons in a population
who are test positive – the true positive rate), specificity
(the proportion of truly non-diseased persons who are
so identified by the test – the true negative rate), and
the positive and negative predictive values (the probabil-
ity that the disease is present or not when the test is
positive or negative, respectively). However, unlike the
previous measures, another set of complementary statis-
tics, the positive and negative likelihood ratios, are less
likely to be affected by background disease prevalence
[11], and are thus considered among the best measures
of test accuracy [12]. Diagnostic likelihood ratio repre-
sents the odds ratio that a positive (or negative) test will
be observed in an infected population compared to the
odds that the same result will be observed in a non-
infected population. A positive likelihood ratio >10 and
a negative likelihood ratio <0.1 generally indicate a test
holds sufficient merit as a useful diagnostic tool [13].
Lastly, test consistency describes diagnostic reliability
(precision) and includes a measure of agreement (Kappa
statistic) between one test and another (e.g., new test
versus a ‘standard’) using dichotomous variables (malaria
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agreement, while 0 indicates the equivalent of chance hav-
ing produced the apparent agreement [14,15].
The XW-P07 has not been listed, or data presented, as
formally evaluated by the World Health Organization’s
Malaria RDT Product Testing Program in Rounds 1
through 5 (2008–2013) [10,16]; therefore, the objective of
this study was to evaluate the performance of this device
as a point-of-care diagnostic test, when compared with ex-
pert microscopy and quantitative real-time PCR (qPCR).
Methods
Site and procedures
Data collection was conducted in Kuala Kencana, a
township near Timika, in April and May 2014. The
health facility was selected as the XW-P07 was in
current use for routine malaria diagnosis with micros-
copy. The annual slide positive rate (SPR) at the Kuala
Kencana Clinic for 2012 and 2013 was 40% (P. falcip-
arum/P. vivax ratio = 1.3:1) and 38% (P. falciparum/P.
vivax = 1:1.2) respectively, indicating no significant
changes in SPR while having a notable shift between the
two years in the proportion of parasite species in favor
of P. vivax. The clinic is equipped with a modern labora-
tory and full-time expert laboratory staff and malaria mi-
croscopists with access to detailed medical records on
all malaria cases reported. The inclusion criteria for
study samples included one or more of the following: 1)
passive patient visit to clinic through either the emer-
gency or outpatient department; 2) patient presenting
with suspected malaria infection that included one or
more of these following symptoms: fever, chills, head-
ache, nausea, vomiting, abdominal pain and/or diarrhea,
myalgia; 3) patient having lived in a malaria-endemic
area or visiting one in the past four weeks; and 4) the
patient may have experienced malaria before [17].
Following informed consent by patient adults or mi-
nors (with parental/legal guardian’s consent), using ster-
ile procedures, a single 3 ml venous blood sample was
collected in a glass Vacutainer® tube containing 5.4 mg
dipotassium (K2) EDTA (Becton, Dickinson and Co.,
New Jersey, USA) from each suspected malaria case.
Blood was used to prepare an RDT with a matched thick
and thin blood slide for microscopy, and qPCR testing.
Approximately 1 ml of blood was transferred into a PCR
sample tube and immediately stored at −20°C. The RDT
and first blood slide reading were recorded immediately.
A second slide reading and PCR test were conducted
within a week of the initial blood draw. Results based on
the RDT and first blood slide reading were provided to
the patient within an hour of sampling and if found in-
fected, malaria treatment provided (artemisinin-based
combination drugs and primaquine as appropriate to
specific infection).The study sampling continued in a consecutive man-
ner until the target sample size was obtained. The mini-
mum sample size (n = 400) for accurately estimating
sensitivity and specificity [18] was based on the reported
lowest RDT sensitivity value (84.4% for P. vivax), the
Mimika 2012 estimated malaria incidence of 0.53 infec-
tions per person-year in the resident population, and an
absolute precision value of 0.05. Those cases with in-
complete information regarding symptom presentations
or laboratory findings, and infections with only P. ovale
or P. malariae parasites based on qPCR were excluded
from the final analysis.
Rapid diagnostic test
The XW-P07 is a rapid, qualitative immunoassay, lateral
flow cassette device that uses 5 μl whole blood for the
detection of P. falciparum-specific histidine rich protein-
2 (P. falciparum-HRP2), P. vivax-specific Plasmodium
lactate dehydrogenase (P. vivax-pLDH), and pan-specific
pLDH for all Plasmodium species (i.e., P. malariae and
P. ovale).
The RDT (Batch 91155A, expiration 31 July 2015) was
used according to the manufacturer’s instructions pro-
vided in the product insert. Reading and interpretation
of test results were done by two trained technicians and
interpreted by consensus within the specified 15–30 min
test window. No test was scored beyond the 30 min
limit. Any test that failed to produce a control band was
considered invalid and the test repeated. Test interpret-
ation criteria are provided in Figure 1. As example, if
matched microscopy or qPCR detected only P. vivax,
while the RDT showed all four bands reactive, the inter-
pretive result of the RDT would be P. falciparum false
positive, P. vivax true positive, P. ovale and/or P. malar-
iae as equivocal and undetermined. Given the low preva-
lence of the latter two species, this study restricted
performance analysis on P. falciparum and P. vivax in-
fections only.
Microscopy
Microscopy and qPCR were used as the reference stan-
dards in this study. With each RDT, a matching thick
and thin blood film (one slide per sample) was prepared
and stained with Giemsa solution (1:10 dilution for ap-
proximately 20 min). Slides were examined using a com-
pound light microscope under x1,000 oil-immersion
magnification by a qualified laboratory technician in the
clinic. All blood films were examined for a minimum of
100 high-magnification fields before being recorded as
either negative for malaria parasites and for the detec-
tion of low density mixed species infections. The para-
site densities were estimated for each sample counted
separately by parasite species. Parasite numbers were re-
ported per 200 white blood cells (WBC) to estimate
Figure 1 XW-P07 test criteria for determination of malaria infection.
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mean WBC count of 8,000/μl blood. Samples were also
categorized into one of four groups based on overall
parasite density (1–100; 101–1,000; 1,001-10,000; and
10,001-100,000 parasites/μl blood).
All slides were subsequently examined by an independ-
ent expert malaria microscopist as an observer-blinded
cross-check and confirmation of first examination. A
third, observer-blinded expert microscopist was used for
slides where there was either discordant or significant dis-
crepancies in findings (infection density or parasite species
discrepancies) between the first and second examiners. In
such cases, the results for the third examination were
regarded as final. All microscopists in this study were ex-
perienced in malaria slide preparation and diagnosis, and
certified through quality assurance procedures.
Quantitative real-time PCR
Quantitative real-time PCR (qPCR) amplification was per-
formed using a Rotor-Gene Q (Qiagen, Hilden, Germany).Parasite DNA (if present) was extracted from whole blood
using Qiagen DNeasy Blood and Tissue Kit (Qiagen,
Hilden, Germany), according to the manufacturer’s in-
structions. Extracted DNA was eluted in a final volume of
100 μl for the first elution and 50 μl for the second. DNA
concentration and purity were measured using a nano-
photometer (Implen GmBH, Munich, Germany) and then
immediately stored at −20°C. Amplification was carried
out in a 20 μl reaction volume, containing 10 μl SYBR
Green (BioRad, California, USA), 0.3 mM of each primer,
30 ng DNA template, and nuclease-free water (Promega,
Wisconsin, USA). A pair of primers was used to amplify
the 18S rRNA gene sequences: PL1473F18 (5′TA CGA
ACG AGA TCT TAA-3′) and PL1679R18 (5′GTT CCT
CTA AGA AGC TTT-3′) for the four Plasmodium
species.
The conditions for the qPCR consisted of initial de-
naturation at 95°C for 10 minutes, 40 cycles amplification
at 95°C for 10 seconds, 50°C for 5 seconds, and 72°C for
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Figure 2 Distribution of blood samples for determining XW-P07
performance.
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2 minutes at 95°C and 68°C each, followed by a stepwise
temperature increase of 0.2°C/s until 90°C, with fluores-
cence acquisition preformed at each temperature transi-
tion. Plasmodium species differentiation was achieved
using melting curve analysis. Above steps and subsequent
data interpretation for qPCR followed Mangold et al. [19]
for detection and identification of each parasite species.
A melting curve analysis with the four species controls
with no template control was used in the RDT perform-
ance evaluation. Graphics were generated using default
software program of Rotor-Gene Q Series Software to
compare against standard melting temperatures for P.
falciparum 75.5-77.5°C, P. vivax 79.0-81.0°C, P. ovale
77.5-79.0°C, and P. malariae 73.5-75.5°C [19].
Statistical analysis
Data was analyzed using Stata 12.0 software (Stata Cor-
poration, College Station, Texas, USA, license no.
08762859510). RDT performance was calculated com-
pared with matched microscopy and qPCR results with
95% confidence intervals (CI) for the following values:
sensitivity (Sn), specificity (Sp), positive predictive value
(PPV), negative predictive value (NPV), positive likelihood
ratio (PLR), negative likelihood ratio (NLR), and Kappa
score. RDT sensitivity was also calculated based on para-
site density. Odds ratios and confidence intervals were cal-
culated for correlation between low parasite counts
(≤100/μl blood) and RDT false negative results based on
matching microscopy and qPCR results; as well as be-
tween low parasite counts and body temperature at the
time of blood sampling. For statistical inference, the
Fisher’s exact test was used for interpretation of false
negative RDT results between malaria infections with
densities above and below 100 parasites/μl blood with sig-
nificance set at p-value of <0.05.
Ethical review
All observations and reporting contained herein are
based on informed consent by volunteers (adults or mi-
nors with their legal guardian’s consent) prior to physical
and laboratory examinations. A unique medical record
number was used as an identifier of each sample and all
information was kept confidential throughout the study.
Ethical review and clearance was obtained from the
Medical and Health Research Ethics Committee (Reference
no. KE/FK/320/EC), Faculty of Medicine, Gadjah Mada
University, Yogyakarta, Indonesia.
Results
Between 10 April and 14 May 2014, 428 suspected mal-
aria patients attending a local clinic in Kuala Kencana,
Mimika, voluntarily provided blood samples (Figure 2).
Of these initial samples, eight had incomplete data, onecase had only P. malariae infection, and four lacked
matching qPCR testing; therefore, only 415 samples
were included in the study and analysis. No adverse
events were recorded with any patient during the blood
draw process or thereafter. In this study, 80% (n = 331)
of patients reported ‘fever’, while only 47.5% (n = 197) ac-
tually had a body temperature ≥37.5°C at the time of
blood sampling. Baseline characteristics of study popula-
tion are shown in Tables 1 and 2.
The RDT cassettes used in this study showed clear line
intensities and had good background clearing after
addition of the buffer solution; however, 3 out 415 tests
failed to produce a ‘control’ line and thus had to be
Table 1 Baseline characteristics of analyzed samples based
on microscopy diagnosis
Male 302/415 (72.8%)
Mean age in years (range) 28.9 years (6 months–76 years)















Positive samples were divided between P. falciparum and P. vivax infections, and
those with mixed species infections were counted separately as P. falciparum and
P. vivax.
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ple. Laboratory test findings are shown in Table 3. RDT
results found 21.0% (87/415) of samples reactive for P.
falciparum, 14.5% (60/415) for P. vivax, and 1.2% (5/
415) with mixed P. falciparum/P. vivax infections. Mi-
croscopy produced a total SPR of 40.5% (168/415); with
P. falciparum slightly more common than P. vivax. To
determine RDT performance using matching micros-
copy, positive slides were divided between P. falciparum
and P. vivax; and those with mixed species infectionsTable 2 Signs and symptoms of suspected malaria cases
with and without parasitaemia based on microscopic
diagnosis





Fever 154 (91.7%) 177 (71.7%)
Chills 68 (40.5%) 52 (21.0%)
Sweating 13 (7.7%) 12 (4.9%)
Nausea 71 (42.3%) 60 (24.3%)
Vomiting 35 (20.8%) 32 (13.0%)
Diarrhea 24 (14.3%) 41 (16.6%)
Headache 71 (42.3%) 57 (23.1%)
Myalgia 52 (31.0%) 55 (22.3%)
Paroxysm: combination chills,
fever, & sweating
12 (7.1%) 5 (2.0%)
≥3 outcomes 97 (57.7%) 77 (31.2%)
≥4 outcomes 60 (35.7%) 26 (10.5%)
Temp ≥37.5°C 112 (66.7%) 85 (34.4%)were counted twice, separately as P. falciparum and P.
vivax. Composite determinations from first, second, and
third slide (if required) examinations were used to calcu-
late final RDT performance. A total of 64 blood slides
(15.4%) out of 415 observations required a third reading
for arbitration over any discrepant results from the initial
first and second examinations. When compared with
matched qPCR, the microscopy error rates for the first
and second examinations were 12% and 8%, respectively;
therefore, the parasite density determinations from the
second reading were used for the final analysis. Overall,
compared to the RDT, microscopy resulted in an in-
creased detection of infection, with Kappa scores (inter-
procedure agreement) between composite microscopy and
qPCR of 0.97 for P. falciparum and 0.92 for P. vivax.
Table 4 provides final RDT performance measures and
95% CI compared with microscopy for detecting P. fal-
ciparum was Sn 92%, Sp 96.6%, PPV 88%, NPV 97.8%,
with Kappa score 0.87; and for P. vivax: Sn 72.9%, Sp
99.1%, PPV 95.4%, NPV 93.4%, with Kappa score 0.79.
Final RDT performance compared with qPCR for detect-
ing P. falciparum was Sn 92%, Sp 96.6%, PPV 88%, NPV
97.8%, with Kappa score 0.87; and for P. vivax: Sn 66%, Sp
99.1%, PPV 95.4%, NPV 90.9%, with Kappa score 0.73.
RDT sensitivity for detecting P. falciparum or P. vivax
was different depending on parasite density as measured
from peripheral blood (Table 5). This difference was sta-
tistically significant for P. falciparum (p = 0.02) and P.
vivax (p <0.001). The RDT achieved 100% sensitivity at
high parasite densities ≥4,800 parasites/μl blood for P.
falciparum and at a lower threshold of ≥640 parasites/μl
for P. vivax. Parasite densities at or below 100/μl in-
creased the probability of the RDT producing a false
negative finding; thus, impacting the overall malaria de-
tection performance of the test. When compared with
microscopy, the odds ratio with low parasite densities
resulting in RDT false negative findings compared to
densities >100/μl was 10.4 (p = 0.05) for P. falciparum,
and 18 (p <0.001) for P. vivax. Similarly, when compared
with qPCR, the odds ratio for false negative results at
low parasite densities was 6.5 (p = 0.2) for P. falciparum
and 16.4 (p <0.001) for P. vivax (Table 6). In RDT compar-
isons, significant differences were seen with P. vivax com-
pared with microscopy and qPCR, but only borderline
significance with P. falciparum and microscopy. However,
after excluding P. vivax densities of ≤100/μl, the RDT per-
formance sensitivity compared with qPCR increased from
66% (95% CI 55.5-75.4%) to 72.8% (61.8-82.1%), along
with adjusted Sp 99.1% (97.3-99.8%), PPV 95.2% (86.5-
99%), NPV 93.5% (90.3-95.9%), PLR 77.7 (25–242), NLR
0.3 (0.2-0.4), and Kappa score 0.79. Similarly, when re-
moving the lower density P. falciparum infections, the
RDT performance compared with qPCR remained nearly
the same, increasing sensitivity only slightly from 92%
Table 3 Summary RDT results compared with matching microscopy and qPCR in 3×3 table
RDT Microscopy Pf Microscopy Pf, Pv Microscopy Pf, Pm Microscopy Pv Microscopy NP
Result PCR PCR PCR PCR PCR PCR PCR PCR PCR PCR PCR
Pf Pf, Pv NP Pf, Pv Pf, Pm Pv Pv, Pm NP Pf Pv NP
Pf 32 0 0 1 0 0 0 0 0 0 8
Pf, Pan 40 2 0 2 2 0 0 0 0 0 0
Pv 1 0 0 0 0 14 0 0 0 0 2
Pv, Pan 0 0 0 0 0 43 0 0 0 0 0
Pan 1 0 0 0 0 0 0 0 0 0 0
Pf, Pv, Pan 0 0 0 2 0 3 0 0 0 0 0
No parasites 3 0 2 0 0 18 1 1 2 8 227
Σobservations 77 2 2 5 2 78 1 1 2 8 237
NP = No parasites. Pf: Plasmodium falciparum, Pv: Plasmodium vivax, Pm: Plasmodium malariae.
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(94–98.3%), PPV 87.6% (79–93.7%), NPV 98.1% (96–
99.3%), PLR 27.5 (15.3-49.3), NLR 0.07 (0.03-0.16), and
Kappa score 0.88.
Normal body temperature recorded at the time of blood
sampling was significantly associated with lower parasite
density in both P. falciparum and P. vivax infections. The
odds ratio of having a normal body temperature (<37.5°C)
and lower parasite densities (≤100/μl) was 12 (95% CI:
1.3-113.7; p = 0.02) for P. falciparum, and 5.5 (95% CI:
1.6-18.9; p = 0.004) for P. vivax.
Discussion
Definitive diagnosis and confirmation of disease status is
the cornerstone of evidence-based medicine. Many malaria-
endemic areas of the world lack sufficient capacity and
resources to accurately diagnose the infection and where
reliance on the presentation of clinical signs and symp-
toms alone are inadequate and imprecise indicators of
specific disease. The WHO recommendations for procure-
ment of malaria RDTs are currently based on theTable 4 RDT performance compared with matching microscop
parasite density
RDT performance Plasmodium falciparum
(n = 88 microscopy +)
Plasmodium
(n = 85 micro
Prevalence 21.2% 20.5%
Sn* 92% (84.3-96.7%) 72.9% (62.2-8
Sp* 96.6% (94.1-98.3%) 99.1% (97.4-9
PPV* 88% (79.6-93.9%) 95.4% (87.1-9
NPV* 97.8% (95.6-99.1%) 93.4% (90.3-9
PLR* 27.4 (15.3-49.1) 80.2 (25.8-249
NLR* 0.08 (0.04-0.17) 0.27 (0.19-0.39
Kappa 0.87 0.79
Sn = sensitivity; Sp = specificity; PPV = positive predictive value; NPV = negative pred
*95% CI.attainment of a set of minimum performance criteria (e.g.,
detection rate/panel detection score, specificity, invalid
rate, etc.) in the WHO Malaria RDT Product Testing Pro-
gram [16] and recommendations established by the WHO
Malaria Policy Advisory Committee in 2012 [20]. Products
that fail to meet the full set of minimum performance cri-
teria are not eligible for procurement by WHO. To some
degree, many other organizations and government pro-
curement authorities also follow the WHO guidelines for
product selection. Based on published findings [10,16], the
XW-P07 RDT has not been tested by the standardized,
laboratory-based WHO program; therefore, an evaluation
regarding its performance for detection of malaria com-
pared to microscopy and qPCR in a point-of-care
operational setting was deemed prudent and essential.
The RDT cassettes were easy to use and provided dis-
tinct, easy to interpret test lines. In only 3 tests did the
RDT fail to show a control line, producing an ‘invalid
rate’ of 0.72%, well within the acceptable limit (<5%)
established by WHO [16]. The RDT showed sensitivity




(n = 88 qPCR +)
Plasmodium vivax
(n = 94 qPCR +)
21.2% 22.6%
2%) 92% (84.3-96.7%) 66% (55.5-75.4%)
9.8%) 96.6% (94.1-98.3%) 99.1% (97.3-99.8%)
9%) 88% (79.6-93.9%) 95.4% (87.1-99.0%)
5.8%) 97.8% (95.6-99.1%) 90.9% (87.3-93.7%)
) 27.4 (15.3-49.1) 70.6 (22.7-220)
) 0.08 (0.04-0.17) 0.34 (0.26-0.46)
0.87 0.73
ictive value; PLR = positive likelihood ratio; NLR = negative likelihood ratio.
Table 5 RDT percent test sensitivity by parasite density based on microscopy for Plasmodium falciparum and Plasmodium
vivax
Parasite density in blood Plasmodium falciparum Plasmodium vivax
n = RDT+/microscopy+ Sn (%) n = RDT+/microscopy+ Sn (%)
1-100/μl 3/5 60 3/14 21.4
101-1,000/μl 14/18 77.8 13/25 52
1,001-10,000/μl 33/34 97 42/42 100
10,001-100,000/μl 31/31 100 4/4 100
Cut-off for 100% Sensitivity 4,800 parasites/μl 640 parasites/μl
Sn = sensitivity.
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compared with microscopy and qPCR. On the other
hand, for P. vivax, the RDT showed the same specificity
>90% and PLR >10; while the overall sensitivity was
much lower when compared with microscopy and qPCR
(73% and 66% respectively), with NLR >0.1 and Kappa
score slightly <0.8. The test specificity for both parasite
species easily met the WHO recommended minimum
performance criteria of >90% (i.e., less than 10% false
positive rate) detection at 200 parasite/μl [20].
An unpublished product evaluation by the XW-P07
manufacturer reported findings from 251 samples com-
pared to microscopy (SPR 16.3%) showing Sn and Sp of
100% for both P. falciparum and P. vivax [8]. A study
performed in Lampung Province, Sumatra, with 400
samples (SPR 36%) showed Sn 91% (85-97%), Sp 99%
(98-100%), PPV 98% (95-100%), NPV 97% (95-99%) for
P. falciparum; and Sn 84% (75-92%), Sp 100%, PPV
100%, NPV 96% (94-98%) for P. vivax based on compari-
sons with matched microscopy [9]. The study in Mimika
demonstrated different predictive values for both parasites
compared to previous investigations which may have been
influenced by the different disease prevalence in eachTable 6 Odds ratios of RDT false negative results
comparing parasite densities below and above 100/μl
blood for Plasmodium falciparum and Plasmodium vivax
Microscopy False True Odds ratio (95% CI) p-value
Negative Positive
Pf ≤100/μl 2 3 10.4 (1.4-77.2) 0.05
Pf >100/μl 5 78
Pv ≤100/μl 11 3 18.0 (4.4-74.5) <0.001
Pv >100/μl 12 59
qPCR False True Odds ratio (95% CI) p-value
Negative Positive
Pf ≤100/μl 1 3 6.5 (0.5-77.3) 0.2
Pf >100/μl 4 78
Pv ≤100/μl 10 3 16.4 (3.9-68.6) <0.001
Pv >100/μl 12 59
Pf: Plasmodium falciparum, Pv: Plasmodium vivax.study [21]. Any direct comparison between studies on
RDT performance may be compromised by other factors
related to location, sample population, background mal-
aria exposure, and degree of acquired partial immunity in
the target populations. This study showed that RDT sensi-
tivity is clearly influenced by parasite density, not an unex-
pected finding based on testing of other products [10,16].
RDTs have been shown to produce lower sensitivity in
areas with more frequent low parasite densities [22,23]. In
this study, body temperature was significantly associated
with parasite density as measured in peripheral blood –
normal temperatures at time of exam produce lower infec-
tion densities while corroborating other observations that
a rise in body temperature is correlated with an increase
in parasite density [24,25].
This product evaluation was not without some under-
lying limitations. Firstly, this study only used RDT cas-
settes from a single lot number; thus, possible inter-lot
variability in performance between product production
periods was not assessed. This study was conducted in a
reasonably controlled setting with trained laboratory
technicians; therefore, extrapolation of findings to areas
under more demanding environmental conditions and
clinical expertise (e.g., remote primary health care clinics)
should be made with caution. Albeit relatively uncommon
infections, P. ovale and P. malariae were not specifically
included in the panel assay (only as a pan-specific pLDH
for all Plasmodium spp.); however, the majority of these
infections in Papua are often coincident (mixed) with
other plasmodial species. In this study, three P. malariae
infections were either mixed with P. falciparum (two
cases) or P. vivax (one case). Lastly, a set minimum of 100
high magnification fields were used for blood examination
of films which possibly contributed to the relatively high
(15.4%) discordant results between the first 2 microsco-
pists. The detection accuracy would have likely been en-
hanced had each reader examined a minimum of 200
fields.
Various host and parasite factors are possible reasons
for varying RDT performance values between different
malaria endemic populations [10,26-31]. Greater sensi-
tivity is a desired attribute and maybe more important
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are correctly diagnosed and promptly treated to avoid
development of disease complications and more severe
infections when left untreated. Undetected cases due to
false negative results also contribute a continuing source
of gametocyte carriers (reservoirs) for sustaining malaria
transmission in an area [31]. Conversely, higher test sen-
sitivity may result in lower test specificity (higher false
positive results), thereby increasing unnecessary malaria
treatments [32]. Typically, P. falciparum infections have
been regarded as the only human plasmodial species re-
sponsible for common causes of severe morbidity and
mortality; however, that general perception has changed
and been challenged by a number of recent studies
showing that P. vivax can produce substantially greater
morbidity manifesting as severe infections, causing acute
and chronic anaemia, and ultimately resulting in death
[33-36]. It is because of these heightened concerns
regards the higher likelihood of more severe outcomes
caused by P. vivax infections, that accurate diagnosis of
this species becomes an even greater priority to ensure
early and effective treatment. An RDT that lacks the ne-
cessary sensitivity for detecting P. vivax (>90% preferred)
and poor exclusion power (a negative diagnostic likeli-
hood ratio of >0.1) to adequately rule out infection pre-
sents a distinct disadvantage to both patient and health
care provider in areas where the parasite is common.
This study showed that XW-P07 has a significantly
lower detection rate for P. vivax than for P. falciparum,
even when excluding low density infections below 100
parasites per μl/peripheral blood. Published WHO prod-
uct evaluation on different malaria RDT products sub-
mitted for testing has shown that targeting P. falciparum
HRP2 has the highest and most consistent detection rate
[16]. However, this conflicts with other findings in which
HRP2-based RDTs have shown a lower performance
value than products using pLDH for detecting P. falcip-
arum, as the pLDH capture system is not affected by a
possible ‘prozone’ effect, parasite antigen polymorphisms
or gene deletions [37-41]. In Myanmar, a study compar-
ing a commonly used RDT utilizing HRP2 and pan
pLDH compared with microscopy demonstrated P. vivax
and P. malariae were detected to a far lesser extent
(lower sensitivity, NPV, and NLR) than P. falciparum
[42]. For P. vivax detection, separate aldolase and pLDH
targeting RDTs have been shown to perform differently
depending on the samples tested, increasing the risk of
misdiagnosis and therefore suggesting that test sensitiv-
ity for P. vivax can be improved by using a combination
of both aldolase and pLDH in a single RDT [43]. The
RDT evaluated in this study only utilizes pLDH for de-
tection of P. vivax, thus one possible explanation for the
inferior sensitivity seen. The XW-P07 showed consider-
ably lower sensitivity and a poor negative likelihoodratio, both measures falling below general acceptance
criteria for detecting P. vivax infections. This is espe-
cially problematic for infections presenting with lower
parasitaemia; thus, RDT results with such limitations
must be interpreted with caution if the test is the sole
method of diagnosis, particularly given the importance
and high prevalence of vivax malaria in the Mimika area.
Furthermore, as a four-band RDT with one control
line and three test lines (Figure 1), the XW-P07 relies on
more antigen/antibody reactions using a single buffer
compared to other RDTs with only three indicator
bands. In areas where the prevalence of P. ovale and P.
malariae is relatively low, a three-band RDT with better
overall performance and able to differentiate P. falciparum
and P.vivax, or possibly a P. falciparum/Pan-malaria test,
may be a better format. Whenever possible, it would also
be prudent and strongly advised to back-up all RDT diag-
nosis, regardless of RDT performance rating, with matched
blood films and proficient microscopic examination.
A recent study in Flores, Indonesia, found that qPCR
revealed almost eight times more Plasmodium infections
when compared with microscopy, taking into account
the high number of sub-microscopic infections in a rela-
tively low transmission area [44]. Molecular methods are
universally accepted as more sensitive than microscopy
alone. However, PCR (e.g., multiplex, real-time or con-
ventional) requires a sophisticated laboratory setting,
trained technicians, entails a longer diagnosis time and
higher costs to support the system; thereby precluding
its routine use in most malaria endemic areas of the
world - Indonesia and Mimika included. New or im-
proved diagnostic methods are in development [45-48]
that may vastly improve diagnostic capabilities and ac-
curacy in challenging locations and basic health care set-
tings. However, until superior, easy-to-use alternatives
are available, both the RDT and microscopy, alone or in
combination, will remain the mainstays for routine
point-of-care malaria diagnosis.
In areas with high prevalence of P. vivax infection,
from a cost-effectiveness point of view, standard expert
microscopy should continue to be used as the reference
gold standard for malaria diagnosis despite the likeli-
hood of missing some low density parasitemia and sub-
microscopic infections. With skilled technicians and
experienced health care providers, microscopy has more
than sufficient, if not excellent, diagnostic capacity in
most instances. All public-funded health facilities and
private clinics in the Mimika Regency must either begin,
or ensure the continuation of microscopy, as their pri-
mary means of malaria diagnosis. Microscopy should be
used for routine confirmation of all RDTs performed in
clinical settings whenever possible. Lastly, in many cir-
cumstances without external funding to support pro-
curement and routine access to RDTs, the sustainability
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to supply disruptions without adequate safeguards and
reliable logistical support in place. The use of micros-
copy, even absent the aid of electricity in the most re-
mote areas, is a sustainable approach and within the
supportive framework of the Indonesian health care
system. Moreover, providing basic electrical power using
efficient solar capture devices and battery storage for a
microscope and basic clinical equipment is well within
the means of most local health budgets. The availability
and routine use of microscopy also enables a facility to
diagnose other important endemic diseases (e.g., tuber-
culosis, lymphatic filariasis, intestinal helminths and
protozoa) and hematological conditions and indicators
without the need of more sophisticated and costly tech-
niques and medical instrumentation.
As malaria represents one of the leading and arguably
most important health concern in the Mimika area,
various health program stakeholders should continue or
adopt a policy of investment in the procurement and
maintenance of quality microscopes, the recruitment of
additional trained laboratory technicians, and organize
regular refresher training on microscopy and RDT
proficiency. Nevertheless, for logistical and operational
rationale, the use of RDTs will continue to play a valu-
able and important role in remote areas for first line
diagnosis of malaria. Health care facilities in remote lo-
cations with limited laboratory capacity should continue
to use high quality malaria RDTs combined with evi-
dence from good clinical observations until microscopy
can be introduced.Conclusions
As a point-of-care device, the XW-P07 provided good test
sensitivity, specificity, positive and negative predictive
values and likelihood ratios, as well as inter-procedure
agreement for detecting P. falciparum infections. For P.
vivax infections, the test provided acceptable specificity
and positive likelihood ratio, but with lower sensitivity,
negative likelihood ratio (below test acceptance criteria),
and inter-procedure agreement comparison. Low parasite
blood densities (≤100 parasites/μl), especially with P. vivax,
increased the probability of false negative test results.
Normal body temperature was strongly associated with
the incident of lower parasitaemia, further complicating
diagnosis. The RDT meets WHO minimum performance
criteria for test specificity (>90%) and invalid rate (<5%).
As vivax malaria is a very common and important parasitic
infection in the population studied, all primary health cen-
ters in the Mimika Regency should begin, or continue
using, expert-level and quality assured standard micros-
copy in a sustainable manner for greater accuracy in mal-
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